Concepedia

Daniel A. Moros

DA

11

Publications

230

Citations

10

H-Index

1968

Active since

Affiliations

Taro Pharmaceuticals (United States)(Current)

Icahn School of Medicine at Mount Sinai

Albert Einstein College of Medicine

Mount Sinai Medical Center

Hebrew University of Jerusalem

Daniel A. Moros is an author at Taro Pharmaceuticals (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top concepts

MedicinePharmacologyPharmacotherapyCardiologyPhysiologyElectrophysiologyAsthmaFertilityArrhythmiaGynecology

Publications per year

1968–2007

11

Publications

11

Treatment of Parkinson's disease in early and late phases. Use of pharmacological agents with special reference to deprenyl (selegiline)

Melvin D. Yahr, MARINA R. MENDOZA, Daniel A. Moros et al. · Acta Neurologica Scandinavica · 1983 · 36 citations

Respiratory dysfunction due to L-Dopa therapy for parkinsnism: Diagnosis using serial pulmonary function tests and respiratory inductive plethysmography

Henry M. Zupnick, Lee K. Brown, Albert Miller et al. · The American Journal of Medicine · 1990 · 31 citations

Asthma, Pulmonary Care, Respiratory Therapy +8

Criteria to Assess In Vivo Performance and Bioequivalence of Generic Controlled‐Release Formulations of Carbamazepine

Meir Bialer, Avi Yacobi, Daniel A. Moros et al. · Epilepsia · 1998 · 22 citations · Full text

Existing and new criteria for bioequivalence evaluation of new controlled release (CR) products of carbamazepine

Meir Bialer, Lidia Arcavi, Sherbel Sussan et al. · Epilepsy Research · 1998 · 21 citations

Pharmaceutical Science, Pharmacological Study, Medicine +5

Who Needs Individual Bioequivalence Studies for Narrow Therapeutic Index Drugs? A Case for Warfarin

Avraham Yacobi, Eric Masson, Daniel A. Moros et al. · The Journal of Clinical Pharmacology · 2000 · 21 citations

Rows per page

1–5 of 11